News

Stocktwits on MSN2h
GSK’s Application To European Authorities For Expanded Use Of RSV Vaccine In Younger Adults Fails To Rejuvenate Retail Optimism
U.K.-based biopharmaceutical company GSK plc (GSK) said on Friday that the European Medicines Agency (EMA) has accepted its ...
GSK falls Friday, underperforms market
GSK PLC GSK shares dropped 2.45% to £15.12 Friday, on what proved to be an all-around poor trading session for the stock ...
Bharat Biotech acquires licence for GSK’s Shigella vaccine development
The partnership includes support for the design of the Phase III trial and assistance in securing external funding.
PipelineReview.com11h
GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older
LONDON, UK I June 13, 2025 I GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted the company’s regulatory ...
GSK's RSV drug Arexvy accepted for regulatory review in Europe
Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...